Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Upregulation of BCMA expression by selinexor

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSilvia NerreterMKMax KoeppelJWJohannes M. Waldschmidt

Discussion

Loading...

Member takes

Overview

Experimental findings show selinexor treatment increases BCMA gene expression, implying enhanced therapeutic efficacy with BCMA-directed immunotherapies.

Key Points

  • This research aims to investigate the impact of selinexor on BCMA expression and its potential to enhance immunotherapy in multiple myeloma.
  • Applied direct Stochastic Optical Reconstruction Microscopy (dSTORM) to measure BCMA expression in myeloma cells.
  • Utilized qPCR to assess gene expression levels following selinexor treatment.
  • Conducted statistical analysis using Mann Whitney test to compare receptor densities.
  • Observed a 4.2-fold increase in BCMA receptor density after 5 days of treatment with selinexor in OPM-2 cells.
  • Detected a corresponding increase in BCMA gene expression of 1.5-fold by day 5.
  • AMO1 cells also demonstrated significant receptor and gene expression increases following selinexor treatment.

Cite This Study

Nerreter et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e148https://doi.org/10.1182/blood-2025-6102
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selinexor potentiates NK cell activation against multiple myeloma2026
  2. 2Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma2025
  3. 3Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape2026 · 1 citations
  4. 4Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma2026
  5. 5XPO1 inhibition by selinexor blocks nucleo-cytoplasmic trafficking of multiple members of the NF-kb family in MPN cell lines and primary myelofibrosis cells2025 · 1 citations